Condition: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Sponsor: First Affiliated Hospital of Zhejiang University
To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.
This description comes directly from the study's public registry record.
Weiyan Zheng, MD · 86-13857187088 · zhengwy2015@163.com
Xuepin Luo, MD · 86-15167157190 · luoxp1603@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital, College of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06046313